Dexcom (DXCM) Notes Payables (2022 - 2025)

Dexcom (DXCM) reported Notes Payables of $1.2 billion for Q3 2025, little changed quarter-over-quarter from $1.2 billion in Q2 2025.

Dexcom (DXCM) Notes Payables (2022 - 2025) Analysis & Trends

Dexcom (DXCM) has 4 years of Notes Payables data on file, last reported at $1.2 billion in Q3 2025.

  • Notes Payables for Q3 2025 came in at $1.2 billion, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $1.2 billion (changed N/A YoY), and the FY2024 annual result was $1.2 billion, changed N/A from the prior year.
  • Notes Payables was little changed at $1.2 billion in Q3 2025 per DXCM's latest filing, from $1.2 billion in the prior quarter.
  • Over five years, Notes Payables peaked at $1.2 billion in Q3 2025 and troughed at $124.2 million in Q3 2023.
  • A 4-year average of $908.3 million and a median of $989.1 million in 2023 frame the typical range for Notes Payables.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Zimmer Biomet Holdings 17.18 Bn 16.77 Bn 1.51 Bn

Historic Data

Download Data
DateValue
Sep 30, 2025 1.21 Bn
Jun 30, 2025 1.21 Bn
Mar 31, 2025 1.21 Bn
Dec 31, 2024 1.20 Bn
Sep 30, 2023 124.20 Mn
Jun 30, 2023 773.80 Mn
Mar 31, 2023 773.20 Mn
Dec 31, 2022 772.60 Mn